Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
12
8
2022
medline:
12
10
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Endogenous/exogenous Cushing's syndrome is characterized by a cluster of systemic manifestations of hypercortisolism, which cause increased cardiovascular risk. Its biological basis is glucocorticoid excess, acting on various pathogenic processes inducing cardiovascular damage. Hypertension is a common feature in Cushing's syndrome and may persist after normalizing hormone excess and discontinuing steroid therapy. In endogenous Cushing's syndrome, the earlier the diagnosis the sooner management can be employed to offset the deleterious effects of excess cortisol. Such management includes combined treatments directed against the underlying cause and tailored antihypertensive drugs aimed at controlling the consequences of glucocorticoid excess. Experts on endocrine hypertension and members of the Working Group on Endocrine Hypertension of the European Society of Hypertension (ESH) prepared this Consensus document, which summarizes the current knowledge in epidemiology, genetics, diagnosis, and treatment of hypertension in Cushing's syndrome.
Identifiants
pubmed: 35950979
doi: 10.1097/HJH.0000000000003252
pii: 00004872-202211000-00001
doi:
Substances chimiques
Antihypertensive Agents
0
Glucocorticoids
0
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2085-2101Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006; 367:1605–1617.
van Staa TP, Leufkrens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93:105–111.
Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin N Am 2005; 34:371–384.
Koper JW, van Rossum EF, van den Akker EL. Glucocorticoid receptor polymorphisms and haplotypes and their expresison in health and disease. Steroids 2014; 92:62–63.
Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001; 86:117–123.
Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27:193–202.
Terzolo M, Reimondo G, Chiodini I, Castello R, Giordano R, Ciccarelli E, et al. Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J Clin Endocrinol Metab 2012; 97:3467–3475.
Tabarin A, Perez P. Pros and cons of screening for occult Cushing syndrome. Nat Rev Endocrinol 2011; 7:445–455.
Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology clinical practice guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175:G1–G34.
Di Dalmazi G, Pasquali R, Beuschlein F, Reincke M. Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur J Endocrinol 2015; 173:M61–M71.
Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline and demographic and clinical characteristics. Eur J Endocrinol 2011; 165:383–392.
Dekkers OM, Horváth-Puhó E, Jørgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab 2013; 98:2277–2284.
Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011; 96:632–642.
Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Neteia-Maier R, et al. High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the Ercusyn Registry. Eur J Endocrinol 2019; 181:461–472.
Ragnarsson O, Olsson DS, Papakokkinou E, Chantzichristos D, Dahlqvist P, Segerstedt E, et al. Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study. J Clin Endocrinol Metab 2019; 104:2375–2384.
Mc Bride MM, Crespo I, Webb SM, Valassi E. Quality of life in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab 2021; 35:101505.
Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, et al. Time to diagnosis of Cushing's syndrome: a meta-analysis based on 5367 patients. J Clin Endocrinol Metab 2020; 105:dgz136.
Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol 2016; 4:611–629.
Ferrau F, Korbonits M. Metabolic comorbidities in Cushing's syndrome. Eur J Endocrinol 2015; 173:M133–M157.
Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61:768–777.
Schernthaner-Reiter MH, Siess C, Micko A, Zauner C, Wolfsberger S, Scheuba C, et al. Acute and life-threatening complications in Cushing syndrome: prevalence, predictors, and mortality. J Clin Endocrinol Metab 2021; 106:e2035–e2046.
Giordano R, Picu A, Marinazzo E, D’Angelo V, Berardelli R, Karamouzis I, et al. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 2011; 75:354–360.
Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34:327–339.
Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA. Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. Eur J Endocrinol 2010; 162:331–340.
Barahona MJ, Resmini E, Vilades D, Pons-Llado G, Leta R, Puig T, Webb SM. Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab 2013; 98:1093–1099.
Papakokkinou E, Olsson DS, Chantzichristos D, Dahlqvist P, Segerstedt E, Olsson T, et al. Excess morbidity persists in patients with Cushing's disease during long-term remission: a Swedish nationwide study. J Clin Endocrinol Metab 2020; 105:2616–2624.
van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM. Management of endocrine disease: mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol 2015; 172:R143–R149.
Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf) 2011; 75:436–442.
Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, Ntali G, et al. Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 2016; 4:569–576.
Hasenmajer V, Sbardella E, Sciarra F, Minnetti M, Isidori AM, Venneri MA. The immune system in Cushing's syndrome. Trends Endocrinol Metab 2020; 31:655–669.
Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011; 33:1413–1432.
Pernicova I, Kelly S, Ajodha S, Sahdev A, Bestwick JP, Gabrovska P, et al. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol 2020; 8:278–291.
Biller BM, Alexander JM, Zervas NT, Hedley-Whyte ET, Arnold A, Klibanski A. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab 1992; 75:1303–1309.
Gicquel C, Le Bouc Y, Luton JP, Girard F, Bertagna X. Monoclonality of corticotroph macroadenomas in Cushing's disease. J Clin Endocrinol Metab 1992; 75:472–475.
Denes J, Korbonits M. The clinical aspects of pituitary tumour genetics. Endocrine 2021; 71:663–674.
Liu APY, Kelsey MM, Sabbaghian N, Park SH, Deal CL, Esbenshade AJ, et al. Clinical outcomes and complications of pituitary blastoma. J Clin Endocrinol Metab 2021; 106:351–363.
Albani A, Perez-Rivas LG, Reincke M, Theodoropoulou M. Pathogenesis of Cushing disease: an update on the genetics of corticotropinomas. Endocr Pract 2018; 24:907–914.
Tatsi C, Flippo C, Stratakis CA. Cushing syndrome: old and new genes. Best Pract Res Clin Endocrinol Metab 2020; 34:101418.
Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1526–1540.
Theodoropoulou M. Glucocorticoid receptors are making a comeback in corticotroph tumorigenesis. Endocrinology 2021; 163:bqab257.
Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999; 84:3823–3830.
Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006; 20:2871–2886.
Riebold M, Kozany C, Freiburger L, Sattler M, Buchfelder M, Hausch F, et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med 2015; 21:276–280.
Roussel-Gervais A, Couture C, Langlais D, Takayasu S, Balsalobre A, Rueda BR, et al. The CABLES1 gene in glucocorticoid regulation of pituitary corticotrope growth and Cushing disease. J Clin Endocrinol Metab 2016; 101:513–522.
Hernández-Ramírez LC, Gam R, Valdés N, Lodish MB, Pankratz N, Balsalobre A, et al. Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's disease. Endocr Rel Cancer 2017; 24:379–392.
Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet 2015; 47:31–38.
Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, Zhou LF, et al. Recurrent gain-of-function USP8 mutations in Cushing's disease. Cell Res 2015; 25:306–317.
Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in USP8 wild-type Cushing's disease. Neuro-Oncology 2019; 21:1273–1283.
Perez-Rivas LG, Theodoropoulou M, Ferraù F, Nusser C, Kawaguchi K, Stratakis CA, et al. The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing's disease. J Clin Endocrinol Metab 2015; 100:E997-E1004.
Albani A, Pérez-Rivas LG, Dimopoulou C, Zopp S, Colón-Bolea P, Roeber S, et al. The USP8 mutational status may predict long-term remission in patients with Cushing's disease. Clin Endocrinol (Oxf) 2018; doi: 10.1111/cen.13802. [Epub ahead of print].
doi: 10.1111/cen.13802.
Uzilov AV, Taik P, Cheesman KC, Javanmard P, Ying K, Roehnelt A, et al. USP8 and TP53 drivers are associated with CNV in a corticotroph adenoma cohort enriched for aggressive tumors. J Clin Endocrinol Metab 2021; 106:826–842.
Casar-Borota O, Boldt HB, Engström BE, Andersen MS, Baussart B, Bengtsson D, et al. Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab 2021; 106:1183–1194.
Song ZJ, Reitman ZJ, Ma ZY, Chen JH, Zhang QL, Shou XF, et al. The genome-wide mutational landscape of pituitary adenomas. Cell Res 2016; 26:1255–1259.
Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson ML, Septier A, et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 2020; 37:123.e5–134.e5.
Young J, Haissaguerre M, Viera-Pinto O, Chabre O, Baudin E, Tabarin A. Management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol 2020; 182:R29–R58.
Perez-Rivas LG, Oßwald A, Knösel T, Lucia K, Schaaf C, Hristov M, et al. Expression and mutational status of USP8 in tumors causing ectopic ACTH secretion syndrome. Endocr Relat Cancer 2017; 24:L73–L77.
Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med 2014; 370:1019–1028.
Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet 2014; 46:613–617.
Cao Y, He M, Gao Z, Peng Y, Li Y, Li L, et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. Science 2014; 344:913–917.
Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assié G, Weigand I, et al. European Network for the Study of Adrenocortical Tumors (ENSAT). Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation. J Clin Endocrinol Metab 2016; 101:3526–3538.
Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014; 46:607–612.
Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 2016; 29:723–736.
Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol 2015; 173:M85–97.
Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006; 38:794–800.
Assié G, Libé R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med 2013; 369:2105–2114.
Kamenicky P, Lacroix A. Mechanism of ectopic hormone receptors in adrenal tumors and hyperplasia. Curr Opin Endocrine Metab Res 2019; 8:206–212.
Chasseloup F, Bourdeau I, Tabarin A, Regazzo D, Dumontet C, Ladurelle N, et al. Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes Endocrinol 2021; 9:813–824.
Vaczlavik A, Bouys L, Violon F, Giannone G, Jouinot A, Armignacco R, et al. KDM1A inactivation causes hereditary food-dependent Cushing's syndrome. Genet Med 2021; 24:374383.
Ross DJ, Linch DC. Cushing's syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 320:646–649.
Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am 2000; 29:43–56.
Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either nonsecreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2:396–405.
Arnaldi G, Angeli A, Atkinson A, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88:5593–5602.
Pecori Giraldi F, Moro M, Cavagnini F. Gender related differences in the presentation and course of Cushing‘s disease. J Clin Endocrinol Metab 2003; 88:1554–1558.
Terzolo M, Reimondo G, Ali A, Bovio S, Daffara F, Paccotti P, Angeli A. Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol 2001; 12: (Suppl 2): S83–S87.
Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing‘s syndrome due to ectopic corticotropin secretion: twenty years‘ experience at the National Institute of Health. J Clin Endocrinol Metab 2005; 90:4955–4962.
Witek P, Witek J, Zieliński G, Podgajny Z, Kamiński G. Ectopic Cushing‘s syndrome in light of modern diagnostic techniques and treatment options. Neuroendocrinol Lett 2015; 36:201–208.
Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long term follow-up. J Clin Endocrinol Metab 2006; 91:371–377.
Leinung MC, Zimmerman D. Cushing‘s disease in children. Endocr Metab Clin North Am 1994; 23:629–639.
Terzolo M, Pia A, Reimondo G. Subclinical Cushing's syndrome: definition and management. Clin Endocrinol (Oxf) 2012; 76:12–18.
Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med 2019; 171:107–116.
Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014; 99:4462–4470.
Patrova J, Kjellman M, Wahrenberg H, Falhammar H. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. Endocrine 2017; 58:267–275.
Kjellbom A, Lindgren O, Puvaneswaralingam S, Löndahl M, Olsen H. Association between mortality and levels of autonomous cortisol secretion by adrenal incidentalomas: a cohort study. Ann Intern Med 2021; 174:1041–1049.
Zhang CD, Li D, Kaur RJ, Ebbehoj A, Singh S, Atkinson EJ, et al. Cardiometabolic outcomes and mortality in patients with adrenal adenomas in a population-based setting. J Clin Endocrinol Metab 2021; 106:3320–3330.
Park J, De Luca A, Dutton H, Malcolm JC, Doyle MA. Cardiovascular outcomes in autonomous cortisol secretion and nonfunctioning adrenal adenoma: a systematic review. J Endocr Soc 2019; 3:996–1008.
Deutschbein T, Reimondo G, Di Dalmazi G, Bancos I, Patrova J, Vassiliadi DA, et al. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol 2022; S2213-8587 (10):499–508.
Androulakis II, Kaltsas G, Piaditis G, Grossman AB. The clinical significance of adrenal incidentalomas. Eur J Clin Invest 2011; 41:552–560.
Morelli V, Eller-Vainicher C, Salcuni AS, Coletti F, Iorio L, Muscogiuri G, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 2011; 26:1816–1821.
Kastelan D, Dzubur F, Dusek T, Poljicanin T, Crncevic-Orlic Z, Kraljevic I, et al. Health-related quality of life and fatigue in patients with adrenal incidentaloma. Endocrine 2011; 40:84–89.
Prete A, Subramanian A, Bancos I, Chortis V, Tsagarakis S, Lang K, et al. Cardiometabolic disease burden and steroid excretion in benign adrenal tumors: a cross-sectional multicenter study. Ann Intern Med 2022; 175:325–334.
Reimondo G, Chiodini I, Puglisi S, Pia A, Morelli V, Kastelan D, et al. Analysis of BCLI, N363S and ER22/23EK polymorphisms of the glucocorticoid receptor gene in adrenal incidentalomas. PLoS One 2016; 11:e0162437.
Di Dalmazi G, Fanelli F, Zavatta G, Ricci Bitti S, Mezzullo M, Repaci A, et al. The steroid profile of adrenal incidentalomas: subtyping subjects with high cardiovascular risk. J Clin Endocrinol Metab 2019; 104:5519–5528.
Morelli V, Reimondo G, Giordano R, Della Casa S, Policola C, Palmieri S, et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 2014; 99:827–834.
Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, et al. ABC Study Group. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens 2015; 33:44–60.
Fardet L, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs 2014; 74:1731–1745.
Pivonello R, De Martino MC, De Leo M, Tauchmanova L, Faggiano A, Lombardi G, et al. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol 2007; 51:1381–1391.
Jha S, Sinaii N, McGlotten RN, Nieman LK. Remission of hypertension after surgical cure of Cushing's syndrome. Clin Endocrinol (Oxf) 2020; 92:124–130.
Pecori Giraldi F, Toja PM, De Martin M, Maronati A, Scacchi M, Omboni S, et al. Circadian blood pressure profile in patients with active Cushing's disease and after long-term cure. Horm Metab Res 2007; 39:908–914.
Zacharieva S, Orbetzova M, Stoynev A, Shigarminova R, Yaneva M, Kalinov K, et al. Circadian blood pressure profile in patients with Cushing's syndrome before and after treatment. J Endocrinol Invest 2004; 27:924–930.
Avenatti E, Rebellato A, Iannaccone A, Battocchio M, Dassie F, Veglio F, et al. Left ventricular geometry and 24-h blood pressure profile in Cushing's syndrome. Endocrine 2017; 55:547–554.
Rebellato A, Grillo A, Dassie F, Sonino N, Maffei P, Martini C, et al. Ambulatory blood pressure monitoring-derived short-term blood pressure variability is increased in Cushing's syndrome. Endocrine 2014; 47:557–563.
Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Nihei M, et al. Exogenous glucocorticoids eliminates or reverses circadian blood pressure variations. J Hypertens 1989; 7:113–120.
Paleń-Tytko JE, Przybylik-Mazurek EM, Rzepka EJ, Pach DM, Sowa-Staszczak AS, Gilis-Januszewska A, et al. Ectopic ACTH syndrome of different origin-diagnostic approach and clinical outcome. Experience of one Clinical Centre. PLoS One 2020; 15:e0242679.
Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46:1227–1235.
Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003; 88:2384–2392.
Stewart PM, Walker BR, Holder G, O’Halloran D, Shackleton CH. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995; 80:3617–3620.
Bailey MA, Mullins JJ, Kenyon CJ. Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome. Hypertension 2009; 54:890–896.
Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62:275–279.
Ritchie CM, Sheridan B, Fraser R, Hadden DR, Kennedy AL, Riddell J, Atkinson AB. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 1990; 76:855–867.
Shibata H, Suzuki H, Maruyama T, Saruta T. Gene expression of angiotensin II receptor in blood cells of Cushing's syndrome. Hypertension 1995; 26 (6 pt 1):1003–1010.
Heaney AP, Hunter SJ, Sheridan B, Brew Atkinson A. Increased pressor response to noradrenaline in pituitary dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1999; 51:293–299.
Jyotsna VP, Naseer A, Sreenivas V, Gupta N, Deepak KK. Effect of Cushing's syndrome: endogenous hypercortisolemia on cardiovascular autonomic functions. Auton Neurosci 2011; 160:99–102.
Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A, Alexandrov AS. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. Eur J Endocrinol 2003; 149:549–553.
Mangos GJ, Whitworth JA, Williamson PM, Kelly JJ. Glucocorticoids and the kidney. Nephrol Carlton Vic 2003; 8:267–273.
Miljic P, Miljic D, Cain JW, Korbonits M, Popovic V. Pathogenesis of vascular complications in Cushing's syndrome. Horm (Athens) 2012; 11:21–30.
Schernthaner-Reiter MH, Siess C, Gessl A, Scheuba C, Wolfsberger S, Riss P, et al. Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission. Endocrine 2018; 56:157–168.
Ferraù F, Korbonits M. Metabolic syndrome in Cushing's syndrome patients. Front Horm Res 2018; 49:85–103.
Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI. Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management. Curr Hypertens Rep 2005; 7:212–218.
Ceccato F, Bernkopf E, Scaroni C. Sleep apnea syndrome in endocrine clinics. J Endocrinol Invest 2015; 38:827–834.
Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, et al. Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol 2003; 41:2275–2279.
Vassiliadi DA, Tsgarakis S. Cardiac hypertrophy in Cushing's syndrome. If not hypertension then what? Endocrine 2017; 56:453–455.
Uziębło-Życzkowska B, Krzesiński P, Witek P, Zieliński G, Jurek A, Gielerak G, et al. Cushing's disease: subclinical left ventricular systolic and diastolic dysfunction revealed by speckle tracking echocardiography and tissue Doppler imaging. Front Endocrinol (Lausanne) 2017; 8:222.
Tadic M, Sala C, Carugo S, Mancia G, Grassi G, Cuspidi C. Left ventricular global longitudinal strain in secondary hypertension: a meta-analysis of echocardiographic studies. Eur J Intern Med 2022; 96:81–89.
Roux C, Kachenoura N, Raissuni Z, Mousseaux E, Young J, Graves MJ, et al. Effects of cortisol on the heart: characterization of myocardial involvement in Cushing's disease by longitudinal cardiac MRI T1 mapping. J Magn Reson Imaging 2017; 45:147–156.
Kamenický P, Redheuil A, Roux C, Salenave S, Kachenoura N, Raissouni Z, et al. Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 2014; 99:E2144–E2153.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41:407–477.
Tona F, Boscaro M, Barbot M, Maritan L, Famoso G, Dal Lin C, et al. New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: a pilot noninvasive study by transthoracic doppler echocardiography. Microvasc Res 2020; 128:103940.
Albiger N, Testa RM, Almoto B, Ferrari M, Bilora F, Petrobelli F, et al. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006; 38:405–410.
Fallo F, Sonino N. Should we evaluate for cardiovascular disease in patients with Cushing's syndrome? Clin Endocrinol (Oxf) 2009; 71:768–771.
Bassareo PP, Zedda AM, Mercuro G. Impairment of arterial compliance in Cushing's syndrome. Eur Endocrinol 2014; 10:161–164.
Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol 2021; 9:847–875.
Nieman LK, Biller BM, Findling JW, Hassan Murad M, Newell-Price J, Savage MO, Tabarin A, Endocrine Society. Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100:2807–2831.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36:1953–2041.
Rudnick KV, Sackett DL, Hirst S, Holmes C. Hypertension in a family practice. Can Med Assoc J 1977; 117:492–497.
Danielson M, Dammström B. The prevalence of secondary and curable hypertension. Acta Med Scand 1981; 209:451–455.
Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147:1289–1293.
Anderson GH Jr, Blakeman N, Streeten DHP. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12:609–615.
Martins LC, Conceição FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. J Hypertens 2012; 30:967–973.
Trifanescu R, Carsote M, Caragheorgheopol A, Hortopan D, Dumitrascu A, Dobrescu M, Poiana C. Screening for secondary endocrine hypertension in young patients. Maedica (Bucur) 2013; 8:108–115.
Aoe M, Okada A, Usui T, Manaka K, Nangaku M, Makita N, et al. Comparison between the clinical characteristics of patients with adrenal incidentalomas and those with hypertension-associated adrenal tumors in a single center in Japan. Endocr J 2020; 67:645–654.
Young WF, Calhoun DA, Lenders JWM, Stowasser M, Textor SC. Screening for endocrine hypertension: an Endocrine Society scientific statement. Endocr Rev 2017; 38:103–122.
Braun LT, Riester A, Oßwald-Kopp A, Fazel J, Rubinstein G, Bidlingmaier M, et al. Toward a diagnostic score in Cushing's syndrome. Front Endocrinol (Lausanne) 2019; 10:766.
León-Justel A, Madrazo-Atutxa A, Alvarez-Rios AI, Infantes-Fontán R, Garcia-Arnés JA, Lillo-Muñozet JA, et al. Spanish CRISALIDA Study Group. A probabilistic model for Cushing's syndrome screening in at-risk populations: a prospective multicenter study. J Clin Endocrinol Metab 2016; 101:3747–3754.
Parasiliti-Caprino M, Bioletto F, Frigerio T, D’Angelo V, Ceccato F, Ferraù F, et al. A new clinical model to estimate the pretest probability of Cushing's syndrome: the Cushing score. Front Endocrinol (Lausanne) 2021; 12:747549.
Vogg N, Kurlbaum M, Deutschbein T, Gräsl B, Fassnacht M, Kroiss M. Method-specific cortisol and dexamethasone thresholds increase clinical specificity of the dexamethasone suppression test for Cushing syndrome. Clin Chem 2021; 67:998–1007.
Ceccato F, Artusi C, Barbot M, Lizzul L, Pinelli S, Costantini G, et al. Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. J Endocrinol Invest 2020; 43:1105–1113.
Alexandraki KI, Kaltsas GA, Isidori AM, Akker SA, Drake WM, Chew SL, et al. The prevalence and characteristic features of cyclicity and variability in Cushing's disease. Eur J Endocrinol 2009; 160:1011–1018.
Galm BP, Qiao N, Klibanski A, Biller BMK, Tritos NA. Accuracy of laboratory tests for the diagnosis of Cushing syndrome. J Clin Endocrinol Metab 2020; 105:dgaa105.
Petersenn S. Biochemical diagnosis of Cushing's disease: screening and confirmatory testing. Review Best Pract Res Clin Endocrinol Metab 2021; 35:101519.
Sherlock M, Scarsbrook A, Abbas A, Fraser S, Limumpornpetch P, Dineen R, et al. Adrenal incidentaloma. Endocr Rev 2020; 41:775–820.
Cambos S, Tabarin A. Management of adrenal incidentalomas: working through uncertainty. Best Pract Res Clin Endocrinol Metab 2020; 34:101427.
Genere N, Kaur RJ, Athimulam S, Thomas MA, Nippoldt T, Van Norman M, et al. Interpretation of abnormal dexamethasone suppression test is enhanced with use of synchronous free cortisol assessment. J Clin Endocrinol Metab 2022; 107:e1221–e1230.
Ueland GÅ, Methlie P, Kellmann R, Bjørgaas M, Åsvold BO, Thorstensen K, et al. Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. Eur J Endocrinol 2017; 176:705–713.
Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. The Lancet 2015; 386:913–927.
Aron DC, Raff H, Findling JW. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:1780–1785.
Frete C, Corcuff JB, Kuhn E, Salenave S, Gaye D, Young J, et al. Noninvasive diagnostic strategy in ACTH-dependent Cushing's Syndrome. J Clin Endocrinol Metab 2020; 105:dgaa409.
Wannachalee T, Turcu AF, Bancos I, Habra MA, Avram AM, Chuang HH, et al. The clinical impact of [68Ga]-DOTATATE PET/CT for the diagnosis and management of ectopic adrenocorticotropic hormone-secreting tumours. Clin Endocrinol (Oxf) 2019; 91:288–294.
Koulouri O, Steuwe A, Gillett D, Hoole AC, Powlson AS, Donnelly NA, et al. A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome. Eur J Endocrinol 2015; 173:M107–M120.
Walia R, Gupta R, Bhansali A, Pivonello R, Kumar R, Singh H, et al. Molecular imaging targeting corticotropin releasing hormone receptor for corticotropinoma: a changing paradigm. J Clin Endocrinol Metab 2020; 106:e1816–e1826.
Bancos I, Taylor AE, Chortis V, Sitch AJ, Jenkinson C, Davidge-Pitts CJ, et al. ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol 2020; 8:773–781.
Petersenn S, Richter PA, Broemel T, Ritter CO, Deutschbein T, Beil FU, et al. German ACC Study Group. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol 2015; 172:415–422.
Bourdeau I, Parisien-La Salle S, Lacroix A. Adrenocortical hyperplasia: a multifaceted disease. Best Pract Res Clin Endocrinol Metab 2020; 34:101386.
Hannah-Shmouni F, Berthon A, Faucz FR, Briceno JM, Maria AG, Demidowich A, et al. Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. Endocr Relat Cancer 2020; 27:403–413.
Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing's syndrome. Best Pract Res Clin Endocrinol Metab 2021; 35:101521.
Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M, et al. Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 2015; 172:R227–R239.
Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, et al. Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab 2014; 99:1623–1630.
Castinetti F, Nieman LK, Reincke M, Newell-Price J. Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metab 2021; 106:2114–2123.
Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, et al. Effectiveness of Metyrapone in treating Cushing's syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab 2015; 100:4146–4154.
Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O, et al. Cabergoline for Cushing's disease: a large retrospective multicenter study. Eur J Endocrinol 2017; 176:305–314.
Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, et al. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 2018; 6:17–26.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsuet A, et al. LINC 3 investigators. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 2020; 8:748–761.
Tritos NA. Adrenally Directed Medical Therapies for Cushing Syndrome. J Clin Endocrinol Metab 2021; 106:16–25.
Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol 2019; 7:855–865.
Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018; 179:G1–G46.
Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol 2015; 172:473–481.
Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautieret JF, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011; 96:2796–2804.
Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S, et al. ERCUSYN Study Group. Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol 2018; 178:399–409.
Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, et al. SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039–2049.
Gheorghiu ML. Updates in the outcomes of radiation therapy for Cushing's disease. Best Pract Res Clin Endocrinol Metab 2021; 35:101514.
Guerin C, Taieb D, Treglia G, Brue T, Lacroix A, Sebag F, et al. Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism? Endocr Relat Cancer 2016; 23:R131–R142.
Reincke M, Ritzel K, Oßwald A, Berr C, Stalla G, Hallfeldt K, et al. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. Eur J Endocrinol 2015; 173:M23–M32.
Reincke M, Albani A, Assie G, Bancos I, Brue T, Buchfelder M, et al. Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol 2021; 184:1–16.
Bancos I, Alahdab F, Crowley RK, Chortis V, Delivanis DA, Erickson D, et al. Therapy of endocrine disease: improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and Subclinical Cushing's syndrome: a systematic review and meta-analysis. Eur J Endocrinol 2016; 175:R283–R295.
Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European society of hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32:1359–1366.
Fallo F, Sonino N, Barzon L, Pistorello M, Pagotto U, Paoletta A, et al. Effect of surgical treatment on hypertension in Cushing's syndrome. Am J Hypertens 1996; 9:77–80.
Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing's disease. Endocr Rev 2015; 36:385–486.
Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, et al. Medical treatment of Cushing's disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne) 2020; 11:648.
Fallo F, Paoletta A, Tona P, Boscaro M, Sonino N. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. J Intern Med 1993; 234:595–598.
Valassi E, Crespo I, Gich I, Rodríguez J, Webb SM. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome. Clin Endocrinol (Oxf) 2012; 77:735–742.
Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, et al. SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039–2049.
Barbot M, Ceccato F, Scaroni C. The pathophysiology and treatment of hypertension in patients with Cushing's syndrome. Front Endocrinol (Lausanne) 2019; 10:321.
Nieman LK. Hypertension and cardiovascular mortality in patients with Cushing syndrome. Endocrinol Metab Clin North Am 2019; 48:717–725.
Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR, et al. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease. Eur J Endocrinol 2020; 182:207–217.
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895–906.
Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol 2015; 200:25–29.